Daiichi Sankyo Company, Limited (DSKYF)
For informational purposes only. Not financial advice. Analysis by Sedat Aydin, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Daiichi Sankyo Company, Limited (DSKYF) with AI Score 55/100 (Hold). Daiichi Sankyo Company, Limited is a global pharmaceutical company focused on researching, developing, and commercializing innovative medicines. Market cap: 0, Sector: Healthcare.
Last analyzed: Mar 17, 2026Daiichi Sankyo Company, Limited (DSKYF) Healthcare & Pipeline Overview
Daiichi Sankyo Company, Limited, a Japanese pharmaceutical company, develops and markets a diverse range of drugs including oncology treatments, cardiovascular medications, and vaccines. With a global presence and a focus on innovative therapies like antibody drug conjugates, Daiichi Sankyo maintains a significant position in the competitive pharmaceutical landscape.
Investment Thesis
Daiichi Sankyo presents a compelling investment case based on its established position in the pharmaceutical industry, diverse product portfolio, and focus on innovative therapies. The company's oncology franchise, particularly Enhertu, is a key growth driver. With a P/E ratio of 17.85 and a profit margin of 14.8%, Daiichi Sankyo demonstrates financial stability. The company's dividend yield of 2.35% offers an additional incentive for investors. Upcoming catalysts include potential regulatory approvals for new indications of existing drugs and advancements in its research and development pipeline. However, potential risks include competition from other pharmaceutical companies and regulatory challenges. The company's beta of -0.30 suggests lower volatility compared to the overall market.
Based on FMP financials and quantitative analysis
Key Highlights
- Market Cap of $32.32B reflects Daiichi Sankyo's significant size and established position in the pharmaceutical industry.
- P/E Ratio of 17.85 indicates the company's valuation relative to its earnings.
- Profit Margin of 14.8% demonstrates the company's ability to generate profit from its revenue.
- Gross Margin of 77.5% showcases the efficiency of Daiichi Sankyo's operations and the value of its products.
- Dividend Yield of 2.35% provides investors with a steady income stream.
Competitors & Peers
Strengths
- Strong oncology pipeline with promising new therapies.
- Established presence in key therapeutic areas.
- Global distribution network.
- Experienced management team.
Weaknesses
- Reliance on a limited number of key products.
- Exposure to generic competition.
- High research and development costs.
- Dependence on regulatory approvals.
Catalysts
- Ongoing: Potential regulatory approvals for new indications of existing drugs.
- Ongoing: Advancements in the research and development pipeline, particularly in oncology.
- Ongoing: Expansion into emerging markets.
- Ongoing: Strategic partnerships and acquisitions.
- Ongoing: Growth in the oncology market.
Risks
- Potential: Intense competition from other pharmaceutical companies.
- Potential: Patent expirations.
- Potential: Regulatory challenges.
- Potential: Economic downturns.
- Ongoing: Reliance on a limited number of key products.
Growth Opportunities
- Expansion of Enhertu: Enhertu, Daiichi Sankyo's anti-HER2 antibody drug conjugate, presents a substantial growth opportunity. The global market for HER2-positive breast cancer therapies is significant, and Enhertu's efficacy has positioned it as a leading treatment option. Further expansion into other HER2-expressing cancers, such as non-small cell lung cancer, could significantly increase its market potential. The collaboration with Guardant Health to develop companion diagnostics will further enhance Enhertu's adoption and effectiveness. Timeline: Ongoing.
- Development of New Oncology Therapies: Daiichi Sankyo's commitment to oncology research and development provides a strong foundation for future growth. The company's pipeline includes several promising new cancer therapies targeting various mechanisms of action. Successful development and commercialization of these therapies could drive significant revenue growth and strengthen Daiichi Sankyo's position in the oncology market. The global oncology market is projected to reach $300 billion by 2025. Timeline: Ongoing.
- Geographic Expansion: Expanding into emerging markets represents a significant growth opportunity for Daiichi Sankyo. These markets, with their growing populations and increasing healthcare spending, offer substantial potential for pharmaceutical sales. Establishing a strong presence in these regions could diversify Daiichi Sankyo's revenue streams and reduce its reliance on developed markets. Key emerging markets include China, India, and Brazil. Timeline: Ongoing.
- Strategic Partnerships and Acquisitions: Forming strategic partnerships and acquiring complementary businesses can accelerate Daiichi Sankyo's growth. Collaborations with biotechnology companies and research institutions can provide access to innovative technologies and drug candidates. Acquisitions can expand Daiichi Sankyo's product portfolio and geographic reach. The pharmaceutical industry is characterized by frequent mergers and acquisitions. Timeline: Ongoing.
- Advancements in Pain Management Therapies: Daiichi Sankyo's mirogabalin, a novel pain medication, addresses a significant unmet need in the treatment of neuropathic pain. The global pain management market is substantial, and effective new therapies are in high demand. Expanding the indications for mirogabalin and developing other pain management products could drive significant growth in this therapeutic area. The global pain management market is projected to reach $90 billion by 2027. Timeline: Ongoing.
Opportunities
- Expansion into emerging markets.
- Strategic partnerships and acquisitions.
- Development of new therapies for unmet medical needs.
- Growth in the oncology market.
Threats
- Intense competition from other pharmaceutical companies.
- Patent expirations.
- Regulatory challenges.
- Economic downturns.
Competitive Advantages
- Patents and intellectual property protection for its innovative drugs.
- Strong brand reputation and established relationships with healthcare providers.
- Extensive research and development capabilities.
- Global distribution network.
- Regulatory expertise and experience.
About DSKYF
Founded in 1899 and headquartered in Tokyo, Japan, Daiichi Sankyo Company, Limited is a global pharmaceutical organization dedicated to creating and supplying innovative pharmaceutical products. The company's operations span research and development, manufacturing, marketing, and sales of pharmaceuticals across the world. Daiichi Sankyo's product portfolio includes treatments in oncology, cardiovascular disease, pain management, and other therapeutic areas. Key products include trastuzumab deruxtecan (Enhertu), an anti-cancer agent, mirogabalin for pain, and edoxaban, an anticoagulant. The company also offers treatments for diabetes, osteoporosis, and various infectious diseases. Daiichi Sankyo has a significant presence in both developed and emerging markets. The company emphasizes research and development, particularly in oncology, and collaborates with other organizations to advance its pipeline. A collaboration with Guardant Health focuses on developing Guardant360 CDx as a companion diagnostic for Enhertu in non-small cell lung cancer. Daiichi Sankyo's long history and diverse product range contribute to its established position in the pharmaceutical industry.
What They Do
- Researches and develops pharmaceutical products.
- Manufactures pharmaceutical products.
- Imports pharmaceutical products.
- Markets pharmaceutical products.
- Sells pharmaceutical products.
- Offers treatments for oncology, cardiovascular diseases, pain management, and other therapeutic areas.
- Provides vaccines for various infectious diseases.
Business Model
- Develops and patents innovative pharmaceutical products.
- Conducts clinical trials to demonstrate the safety and efficacy of its products.
- Obtains regulatory approvals from agencies such as the FDA and EMA.
- Manufactures and distributes its products globally.
- Markets and sells its products through a network of sales representatives and distributors.
Industry Context
Daiichi Sankyo operates in the global pharmaceutical industry, a sector characterized by intense competition, high research and development costs, and stringent regulatory requirements. The industry is driven by innovation, with companies constantly seeking to develop new and improved treatments for various diseases. The market for oncology drugs is particularly competitive and lucrative. Daiichi Sankyo's focus on antibody drug conjugates positions it well within this landscape. The company competes with other major pharmaceutical companies, including CHALF, HLNCF, HOCPF, IPSEY, and OTSKY, all vying for market share in key therapeutic areas.
Key Customers
- Hospitals and clinics
- Pharmacies
- Healthcare providers
- Patients
- Government healthcare agencies
Financials
Chart & Info
Daiichi Sankyo Company, Limited (DSKYF) stock price: Price data unavailable
Latest News
-
Madrigal sees a stock sell-off; ex-Novartis exec heads to Daiichi
BioPharma Dive · Feb 20, 2026
-
Recession-Resilient Asian Stock Picks: TSMC, SK Hynix Among This Analyst's Top 10
benzinga · Aug 7, 2024
Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for DSKYF.
Price Targets
Wall Street price target analysis for DSKYF.
MoonshotScore
What does this score mean?
The MoonshotScore rates DSKYF's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
Competitors & Peers
Leadership: Hiroyuki Okuzawa
Unknown
Information about Hiroyuki Okuzawa's background is not available in the provided context. Therefore, a detailed career history, education, previous roles, and credentials cannot be provided. Further research would be needed to provide a comprehensive biography.
Track Record: Information about Hiroyuki Okuzawa's track record is not available in the provided context. Therefore, key achievements, strategic decisions, and company milestones under their leadership cannot be provided. Further research would be needed to provide a detailed analysis.
DSKYF OTC Market Information
The OTC Other tier, where DSKYF trades, represents the lowest tier of the OTC market. Companies in this tier often have limited or no financial disclosure, making it difficult for investors to assess their financial health and operational performance. Unlike companies listed on major exchanges like the NYSE or NASDAQ, OTC Other companies do not have to meet minimum listing standards, which include requirements for financial reporting, corporate governance, and minimum share price. This lack of regulation increases the risk associated with investing in these companies.
- OTC Tier: OTC Other
- Disclosure Status: Unknown
- Limited financial disclosure increases the risk of investing in DSKYF.
- Lower liquidity can lead to price volatility and difficulty in executing trades.
- Lack of regulatory oversight compared to major exchanges.
- Potential for fraud or manipulation.
- Information asymmetry due to limited public information.
- Verify the company's registration and legal status.
- Attempt to locate and review any available financial statements.
- Research the company's management team and their track record.
- Assess the company's business model and competitive landscape.
- Understand the risks associated with investing in OTC stocks.
- Consult with a financial advisor.
- Check for any regulatory actions or legal disputes involving the company.
- Established history dating back to 1899.
- Global presence and operations.
- Diverse product portfolio.
- Focus on research and development.
- Partnerships with reputable organizations.
Daiichi Sankyo Company, Limited Stock: Key Questions Answered
What does Daiichi Sankyo Company, Limited do?
Daiichi Sankyo Company, Limited is a global pharmaceutical company involved in the research, development, manufacturing, and marketing of a wide range of pharmaceutical products. Its portfolio includes treatments for various therapeutic areas, including oncology, cardiovascular diseases, and pain management. The company's key products include trastuzumab deruxtecan (Enhertu), mirogabalin, and edoxaban. Daiichi Sankyo operates globally, serving hospitals, clinics, pharmacies, and patients through its network of sales representatives and distributors. The company focuses on innovation and strategic partnerships to drive growth and address unmet medical needs.
What do analysts say about DSKYF stock?
Analyst consensus on DSKYF stock is currently unavailable. Key valuation metrics to consider include the company's P/E ratio of 17.85 and its dividend yield of 2.35%. Growth considerations include the potential for Enhertu and other pipeline drugs, as well as expansion into emerging markets. Investors should conduct their own research and consider their individual risk tolerance before making any investment decisions. Further AI analysis is pending.
What are the main risks for DSKYF?
The main risks for Daiichi Sankyo include intense competition from other pharmaceutical companies, patent expirations, regulatory challenges, and economic downturns. The company also faces risks associated with its reliance on a limited number of key products. Generic competition could erode sales of established drugs. Regulatory setbacks could delay or prevent the approval of new therapies. Economic downturns could reduce healthcare spending and negatively impact sales. Investors should carefully consider these risks before investing in DSKYF.
What are the key factors to evaluate for DSKYF?
Daiichi Sankyo Company, Limited (DSKYF) currently holds an AI score of 55/100, indicating moderate score. Key strength: Strong oncology pipeline with promising new therapies.. Primary risk to monitor: Potential: Intense competition from other pharmaceutical companies.. This is not financial advice.
How frequently does DSKYF data refresh on this page?
DSKYF prices update in real time during U.S. market hours (9:30 AM-4:00 PM ET, weekdays). Fundamentals refresh after quarterly or annual filings. Analyst ratings and AI insights update daily. News is aggregated continuously from financial sources.
What has driven DSKYF's recent stock price performance?
Recent price movement in Daiichi Sankyo Company, Limited (DSKYF) can be influenced by earnings results, analyst revisions, sector rotation, and broader market sentiment. Notable catalyst: Strong oncology pipeline with promising new therapies.. Check the News and Technical Analysis tabs for the latest drivers. Past performance does not predict future results.
Should investors consider DSKYF overvalued or undervalued right now?
Determining whether Daiichi Sankyo Company, Limited (DSKYF) is overvalued or undervalued requires examining multiple metrics. Compare valuation ratios (P/E, P/S, EV/EBITDA) against sector peers for a comprehensive view.
What research should beginners do before buying DSKYF?
Before investing in Daiichi Sankyo Company, Limited (DSKYF), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) what Wall Street analysts recommend and their price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Information is based on available data and may be subject to change.
- OTC market data may be less reliable than exchange-listed data.